Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
The Lancet. Haematology|August 21, 2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trialPaula Cramer, Moritz Fürstenau, Sandra Robrecht, et al.
The Lancet. Oncology|August 18, 2018
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trialPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.
European Journal of Haematology|December 9, 2015
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemiaChristian Maurer, Natali Pflug, Jasmin Bahlo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.
Blood|April 15, 2024
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trialMoritz Fürstenau, Adam Giza, Jonathan Weiss, et al.
Haematologica|February 29, 2020
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trialPaula Cramer, Julia V Tresckow, Sandra Robrecht, et al.
Blood|November 10, 2021
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemiaPetra Langerbeins, Can Zhang, Sandra Robrecht, et al.
Blood|October 22, 2015
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trialKirsten Fischer, Jasmin Bahlo, Anna Maria Fink, et al.
Blood|April 15, 2024
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapiesPetra Langerbeins, Adam Giza, Sandra Robrecht, et al.
Leukemia & Lymphoma|August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaGraeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
Pageof 7